Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Dan to be featured on the "2 Bulls in a China Shop" podcast

<< Previous

Bullboard Posts

Next >>

Comment by WalkOverTheStrton Jun 07, 2021 10:05pm

195 Views

Post# 33345670

RE:Dan to be featured on the "2 Bulls in a China Shop" podcast

Yes Kyle was really open to taking questions, I lobbed some over too a few weeks back :)

"""

Kyle003p

Bullish

06:05 PM

$ATBPF

We just finished recording with Dan Legault, the episode should be available wednesday afternoon. Thanks again to you guys for providing almost half of the questions, I think we were able to get through all of them!

We'll post a link once it goes live

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages